Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
125
datasets available to search
ShareScore release 0.9.0
Dataset results
125 results for “small molecule inhibitor”
Allosteric Modulation of YAP/TAZ-TEAD Interaction by Palmitoylation and Small Molecule Inhibitors
<p>The tar file contains 3 directories, each of which contains all of the simulation input files (pdb, prmtop, inpcrd) and trajectory files (nc) for the simulations run. </p><ol><li>TEAD_Only: Simulations of the TEAD protein in the apo, inhibitor(inh)-bound, palmitate(plt)-bound, or palmitic acid(plm)-bound form </li><li>YAP-TEAD: Simulations of the YAP-TEAD heterodimer in the apo, inhibitor(inh)-bound, palmitate(plt)-bound, or palmitic acid(plm)-bound form </li><li>TAZ-TEAD: Simulations of the TAZ-TEAD heterodimer in the apo, inhibitor(inh)-bound, palmitate(plt)-bound, or palmitic acid(plm)-bound form </li></ol>
Regulatory spine RS3 residue of protein kinases: a lipophilic bystander or a decisive element in the small-molecule kinase inhibitor binding?
<p>Datasets related to publication: </p> <p>Shevchenko E, Pantsar T: Regulatory spine RS3 residue of protein kinases: a lipophilic bystander or a decisive element in the small-molecule kinase inhibitor binding?. <em><em>Biochem Soc Trans</em></em> 28 February 2022; 50 (1): 633–648</p> <p>https://doi.org/10.1042/bst20210837</p> <p> </p> <p> </p>
Data from: Pleomorphic effects of three small-molecule inhibitors on transcription elongation by <em>Mycobacterium tuberculosis</em> RNA polymerase
Open the record for dataset details and reuse information.
Identification of a small molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical models
<p><span>T cell immunoglobulin and mucin-containing molecule 3 (Tim-3), expressed in dysfunctional and exhausted T cells, has been widely acknowledged as a promising immune checkpoint target for tumor immunotherapy. Here, using a strategy combining virtual and functional screening, we identified a compound named ML-T7 that targets the FG-CC' cleft of Tim-3, a highly conserved binding site of </span><span>phosphatidylserine</span><span> (PtdSer) and carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). ML-T7 enhanced the survival and antitumor activity of </span><span>primary CD8<sup>+</sup> cytotoxic T lymphocytes (CTLs) and human chimeric antigen receptor (CAR) T cells and reduced their exhaustion </span><span>in vitro and in vivo</span><span>. In addition, ML-T7 promoted NK cells' killing activity and DC antigen-presenting capacity, consistent with the reported activity of Tim-3.</span><span> Notably, ML-T7 strengthened DCs' functions through both Tim-3 and Tim-4, consistent with the hypothesis that Tim-4 contains a similar FG-CC' loop. Intraperitoneal dosing of ML-T7 showed comparable tumor inhibitory effects to Tim-3 blocking antibody. ML-T7 reduced syngeneic tumor progression in both wildtype and Tim-3 humanized mice and alleviated the immunosuppressive microenvironment. Furthermore, combined ML-T7 and anti-PD-1 therapy had greater therapeutic efficacy than monotherapy in mice, supporting further development of ML-T7 for tumor immunotherapy. Our study demonstrates a potential small molecule for selectively blocking Tim-3 and warrants further study.</span></p>
Shutting Down Shigella Secretion: Characterizing Small Molecule Type Three Secretion System ATPase Inhibitors
<p>Spa47 inhibition data from "Shutting Down <em>Shigella</em> Secretion: Characterizing Small Molecule Type Three Secretion System ATPase Inhibitors".</p>
Data from: Small molecule inhibitor of tau self-association in a mouse model of tauopathy: A preventive study in P301L tau JNPL3 mice
<p><span class="TextRun SCXW44549199 BCX0"><span class="NormalTextRun SCXW44549199 BCX0">Advances in </span><span class="NormalTextRun SCXW44549199 BCX0">tau biology and </span><span class="NormalTextRun SCXW44549199 BCX0">the </span><span class="NormalTextRun SCXW44549199 BCX0">difficulties of</span><span class="NormalTextRun SCXW44549199 BCX0"> amyloid-directed </span><span class="NormalTextRun SpellingErrorV2Themed SCXW44549199 BCX0">immuno</span><span class="NormalTextRun SpellingErrorV2Themed SCXW44549199 BCX0">therapeutics</span><span class="NormalTextRun SCXW44549199 BCX0"> have heightened interest in tau as a target for </span><span class="NormalTextRun SCXW44549199 BCX0">small molecule </span><span class="NormalTextRun SCXW44549199 BCX0">drug discovery for neurodegenerative diseases. </span><span class="NormalTextRun SCXW44549199 BCX0">Here</span><span class="NormalTextRun SCXW44549199 BCX0">,</span><span class="NormalTextRun SCXW44549199 BCX0"> we </span><span class="NormalTextRun SCXW44549199 BCX0">evaluate</span><span class="NormalTextRun SCXW44549199 BCX0">d</span> <span class="NormalTextRun SCXW44549199 BCX0">OLX-07010</span><span class="NormalTextRun SCXW44549199 BCX0">, a small molecule inhibitor of tau self-association,</span> <span class="NormalTextRun SCXW44549199 BCX0">for the prevention of </span><span class="NormalTextRun SCXW44549199 BCX0">tau aggregat</span><span class="NormalTextRun SCXW44549199 BCX0">ion</span><span class="NormalTextRun SCXW44549199 BCX0">. </span><span class="NormalTextRun SCXW44549199 BCX0">The primary endpoint of the study was </span><span class="NormalTextRun SCXW44549199 BCX0">statistically significant </span><span class="NormalTextRun SCXW44549199 BCX0">reduction of insoluble tau aggregates in treated </span><span class="NormalTextRun SCXW44549199 BCX0">JNPL3 </span><span class="NormalTextRun SCXW44549199 BCX0">mice compared </span><span class="NormalTextRun SCXW44549199 BCX0">with </span><span class="NormalTextRun SCXW44549199 BCX0">V</span><span class="NormalTextRun SCXW44549199 BCX0">ehicle-control</span><span class="NormalTextRun SCXW44549199 BCX0"> mice. </span><span class="NormalTextRun SCXW44549199 BCX0">S</span><span class="NormalTextRun SCXW44549199 BCX0">econdary endpoints were dose-dependent reduction of insoluble tau aggregates, reduction of phosphorylated tau, and reduction of soluble tau.</span> <span class="NormalTextRun SCXW44549199 BCX0">This study was performed in JNPL3 mice, which are representative of inherited forms of 4-repeat tauopathies with the P301L tau mutation</span><span class="NormalTextRun SCXW44549199 BCX0"> (</span><span class="NormalTextRun SpellingErrorV2Themed SCXW44549199 BCX0">eg</span><span class="NormalTextRun SCXW44549199 BCX0">, progressive supranuclear palsy</span><span class="NormalTextRun SCXW44549199 BCX0"> and</span><span class="NormalTextRun SCXW44549199 BCX0"> frontotemporal dementia</span><span class="NormalTextRun SCXW44549199 BCX0">)</span><span class="NormalTextRun SCXW44549199 BCX0">. The P301L mutation makes tau prone to aggregation; therefore, JNPL3 mice present a more challenging target than mouse models of human tau without mutations. </span><span class="NormalTextRun SCXW44549199 BCX0">JNPL3 mice </span><span class="NormalTextRun SCXW44549199 BCX0">were treated </span><span class="NormalTextRun SCXW44549199 BCX0">from 3 to 7 months</span> <span class="NormalTextRun SCXW44549199 BCX0">of</span> <span class="NormalTextRun SCXW44549199 BCX0">age with </span><span class="NormalTextRun SCXW44549199 BCX0">V</span><span class="NormalTextRun SCXW44549199 BCX0">ehicle</span><span class="NormalTextRun SCXW44549199 BCX0">, </span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW44549199 BCX0">30 mg</span><span class="NormalTextRun SCXW44549199 BCX0">/kg compound</span><span class="NormalTextRun SCXW44549199 BCX0"> dose</span><span class="NormalTextRun SCXW44549199 BCX0">,</span> <span class="NormalTextRun SCXW44549199 BCX0">or </span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW44549199 BCX0">40 mg</span><span class="NormalTextRun SCXW44549199 BCX0">/kg compound</span><span class="NormalTextRun SCXW44549199 BCX0"> dose</span><span class="NormalTextRun SCXW44549199 BCX0">. Biochemical </span><span class="NormalTextRun SCXW44549199 BCX0">methods were used to evaluate self-associated tau, insoluble tau aggregates, total tau</span><span class="NormalTextRun SCXW44549199 BCX0">,</span><span class="NormalTextRun SCXW44549199 BCX0"> and phosphorylated tau in the hindbrain</span><span class="NormalTextRun SCXW44549199 BCX0">,</span><span class="NormalTextRun SCXW44549199 BCX0"> cortex</span><span class="NormalTextRun SCXW44549199 BCX0">,</span><span class="NormalTextRun SCXW44549199 BCX0"> and hippocampus.</span> <span class="NormalTextRun SCXW44549199 BCX0">T</span><span class="NormalTextRun SCXW44549199 BCX0">he </span><span class="NormalTextRun SCXW44549199 BCX0">V</span><span class="NormalTextRun SCXW44549199 BCX0">ehicle group had higher levels of insoluble tau </span><span class="NormalTextRun SCXW44549199 BCX0">in the hindbrain </span><span class="NormalTextRun SCXW44549199 BCX0">than the </span><span class="NormalTextRun SCXW44549199 BCX0">B</span><span class="NormalTextRun SCXW44549199 BCX0">aseline group</span><span class="NormalTextRun SCXW44549199 BCX0">;</span> <span class="NormalTextRun SCXW44549199 BCX0">treatment with </span><span class="NormalTextRun SCXW44549199 BCX0">40 mg/kg</span> <span class="NormalTextRun SCXW44549199 BCX0">compound </span><span class="NormalTextRun SCXW44549199 BCX0">dose prevented this increase. </span><span class="NormalTextRun SCXW44549199 BCX0">In the cortex, t</span><span class="NormalTextRun SCXW44549199 BCX0">he levels of insoluble tau were similar in the </span><span class="NormalTextRun SCXW44549199 BCX0">B</span><span class="NormalTextRun SCXW44549199 BCX0">aseline and </span><span class="NormalTextRun SCXW44549199 BCX0">V</span><span class="NormalTextRun SCXW44549199 BCX0">ehicle </span><span class="NormalTextRun SCXW44549199 BCX0">groups</span><span class="NormalTextRun SCXW44549199 BCX0">,</span> <span class="NormalTextRun SCXW44549199 BCX0">indicating</span><span class="NormalTextRun SCXW44549199 BCX0"> that the pathological phenotype of these mice was beginning to </span><span class="NormalTextRun SCXW44549199 BCX0">emerge</span><span class="NormalTextRun SCXW44549199 BCX0"> at the </span><span class="NormalTextRun SCXW44549199 BCX0">study </span><span class="NormalTextRun SCXW44549199 BCX0">endpoint </span><span class="NormalTextRun SCXW44549199 BCX0">and that</span><span class="NormalTextRun SCXW44549199 BCX0"> the</span><span class="NormalTextRun SCXW44549199 BCX0">re was a delay in the</span><span class="NormalTextRun SCXW44549199 BCX0"> development of the phenotype of the model as originally characterized.</span> <span class="NormalTextRun SCXW44549199 BCX0">No drug-related adverse effects were </span><span class="NormalTextRun SCXW44549199 BCX0">observed</span><span class="NormalTextRun SCXW44549199 BCX0"> during the 4-month treatment period. </span></span><span class="EOP SCXW44549199 BCX0"> </span></p>
Identification of a small molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical models
Open the record for dataset details and reuse information.
Data from: Small molecule inhibitor of tau self-association in a mouse model of tauopathy: A preventive study in P301L tau JNPL3 mice
Open the record for dataset details and reuse information.
Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer
ClinicalTrials.gov study NCT00579683. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)
ClinicalTrials.gov study NCT02259114. IPD Sharing: YES. Countries: 0. Publications: 2.
Discovery of Novel small-molecule dual inhibitor targeting toll-like receptors 7 and 9
<p>The data sets contained the MD simulation of TLR7-TIC10g and TLR9-TIC10g complexes.</p>
Identification of covalent small-molecule inhibitors of STING
GEO Series GSE113933. Mus musculus. 12 samples. Type: Expression profiling by high throughput sequencing.
Rapid and synchronous chemical induction of replicative-like senescence via a small molecule inhibitor [bulk RNA-seq]
GEO Series GSE238252. Homo sapiens. 14 samples. Type: Expression profiling by high throughput sequencing.
First in class small molecule inhibitor of oncogene AVIL in glioblastoma
GEO Series GSE268857. Homo sapiens. 2 samples. Type: Expression profiling by array.
Development of RelB-Targeting Small Molecule Inhibitors of Non-canonical NF-kB Signaling with Antitumor Efficacy
GEO Series GSE288086. Homo sapiens. 9 samples. Type: Expression profiling by high throughput sequencing.
Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity
GEO Series GSE215847. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
Rapid induction and long-term self-renewal of primitive neural precursors from human embryonic stem cells by small molecule inhibitors
GEO Series GSE28595. Homo sapiens. 6 samples. Type: Expression profiling by array.
Rapid and synchronous chemical induction of replicative-like senescence via a small molecule inhibitor [CUT&TAG]
GEO Series GSE238253. Homo sapiens. 6 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Preventive Treatment with a CD73 Small Molecule Inhibitor Enhances Immune Surveillance in K-Ras Mutant Pancreatic Intraepithelial Neoplasia
GEO Series GSE273209. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing; Other.
Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase
GEO Series GSE59223. Homo sapiens. 22 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.